Drug Approval | September 30, 2022
Lupin receives US FDA approval for Mirabegron Extended-Release tablets
Mirabegron Extended-Release Tablets, 25 mg and 50 mg, had estimated annual sales of US $2.4 billion in US
Mirabegron Extended-Release Tablets, 25 mg and 50 mg, had estimated annual sales of US $2.4 billion in US
The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility
In the next six months, the program aims to screen 4,000 women from underprivileged communities in and around Mathura
This will be an added advantage for Supriya Lifescience Limited in the European market.
He is a seasoned professional having worked in reputed corporates in API business with over 35+ years of experience covering manufacturing, general management, and business
‘PathoDetect HPV Detection Test’ detects and discriminates the presence of high-risk HPV strains including 16 and 18 which cause most of the cervical cancers.
Dr. Bunker will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine.
The second day of Arogya Manthan 2022 had panel discussions with eminent thought leaders from relevant public and private sector organizations
Sud has more than 32 years of work experience with different companies like Clivient, Jubilant Life Sciences, Piramal Enterprises, Parabolic Drugs, Orchid Chemicals and Pharmaceuticals, Ranbaxy Labs, and Lupin
Subscribe To Our Newsletter & Stay Updated
